A twenty year perspective on melanoma therapy.

Area of Science:

• Oncology
• Immunology
• Cancer Therapeutics

Background:

• Melanoma treatment historically relied on less effective cytokine immunotherapy.
• Immune checkpoint inhibitors, such as CTLA-4 antibodies, showed promise.
• PD-1 antibodies have since become a cornerstone of advanced melanoma treatment.

Purpose of the Study:

• To review the transformative impact of immunotherapy and targeted therapies on melanoma treatment.
• To highlight the significant advancements in melanoma outcomes during the 2010s.

Main Methods:

• Review of immunotherapy advancements, including cytokine therapy, CTLA-4, and PD-1 antibodies.
• Analysis of the development and impact of BRAF inhibitors and combination BRAF/MEK therapy.
• Examination of treatment outcomes in melanoma compared to other cancer types.

Main Results:

• PD-1 antibodies dramatically improved melanoma treatment landscape, enabling immunotherapy for over half of advanced cancer patients.
• BRAF mutations are common in melanoma (nearly 50%), leading to effective targeted therapies.
• BRAF inhibitors and BRAF/MEK combination therapy showed significant success in melanoma.
• Melanoma experienced unprecedented outcome improvements in the 2010s.

Conclusions:

• Immunotherapy, particularly PD-1 blockade, and targeted therapies like BRAF/MEK inhibitors have fundamentally changed melanoma management.
• Melanoma treatment advancements in the last decade surpass those seen in other cancer types.